摘要
The recent approval of pembrolizumab as second-line treatment for any solid tumor with high-level microsatellite instability or mismatch repair deficiency agnostic of tissue and origin1 has shattered a glass ceiling for immune checkpoint inhibitors.No longer bound to a specific cancer diagnosis but rather a biomarker,pembrolizumab has heightened a burgeoning optimism towards the drug class.Yet how these agents should carve out additional
The recent approval of pembrolizumab as second-line treatment for any solid tumor with high-level microsatellite instability or mismatch repair deficiency agnostic of tissue and origin1 has shattered a glass ceiling for immune checkpoint inhibitors. No longer bound to a specific cancer diagnosis but rather a biomarker, pembrolizumab has heightened a burgeoning optimism towards the drug class. Yet how these agents should carve out additional indications is subject to fierce debate,
